Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-043123

Chief Business Development Off sold 417 shares at $40.00 ($16,680)

  • Chief Business Development Off acquired 417 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-07-20 Option exercise +417 $6.27 $2,615 417 D
BENZENO SHARON Chief Business Development Off 2020-07-20 Sale −417 $40.00 $16,680 0 D
Derivatives
BENZENO SHARON Chief Business Development Off 2020-07-20 Option exercise · Stock Option (Right to Buy) −417 3,750 D
Open-market sales · 417 sh · avg $40.00 · $16,680
Loading xslF345X03/doc4.xml…